Advertisement

Topics

Medical Affairs Reputations: NonSmall Cell Lung Carcinoma EU5 2018 [Report Updated: 01022018] Prices from USD $6365

21:24 EDT 5 Apr 2018 | BioPortfolio Reports




Compare 11 NSCLC medical affairs teams. See how your team stacks up to the market leader


In the EU5, several of the NSCLC medical affairs teams we surveyed are running neck and neck with at least one rival. The 150 medical oncologists we polled say that nearly every team needs improvement in two or more areas, but are those targeted improvements enough to put your team ahead of the competition?


Discover all the ways you can improve your medical affair services in Medical Affairs Reputations: NSCLC EU5. Comparing 11 major NSCLC treatments from Roche, Eli Lilly, AstraZeneca, Merck Sharp Dohme, BMS, Novartis, and Pfizer, this detailed report reveals:


How medical oncologists rate your team overall, and on 12 key medical affairs services.

Which medical affairs services are most important.

How, and how often medical oncologists want to meet with your team.

What you can do to improve your medical affairs services.


It's time to find out exactly how well your medical affairs team is performing against fierce competition and establish an action plan to gain competitive advantage.


Interested in the US market? Click here to see the US Edition.






Top Takeaways


All to play for at the top, limited options at the bottom. Only 3 points separate the top 2 leading brands in terms of overall quality of interactions, whereas brands at the bottom could struggle to make up ground.

Information is the 1 priority. The most important medical affairs services all relate to providing information that doctors can use to make better treatment decisions.

Huge variations in activity. In the past six months, only 2 of the 13 teams interacted with more than 70% of doctors surveyed, and the least active teams saw no more than 53% of them.

Doctors want to see teams inperson and not too often. The report reveals how, and how frequently your team should engage.

Digital interaction still some way off becoming the norm. For the most part, doctors want personal interactions, not emails or phone calls.


Insight into Medical Affairs Teams for These 12 NSCLC Treatments


Avastin bevacizumab; Roche

Cyramza ramucirumab; Eli Lilly

Giotrif afatinib; Boehringer Ingelheim

Iressa gefitinib; AstraZeneca

Keytruda pembrolizumab; Merck Sharp Dohme

Opdivo nivolumab; BristolMyers Squibb

Tagrisso osimertinib; AstraZeneca

Tarceva erlotinib; Roche

Tecentriq atezolizumab; Roche

Xalkori crizotinib; Pfizer

Zykadia ceritinib; Novartis


A Competitive View of Your Medical Affairs Team


Developed with the help of medical affairs specialists, this report gives you an indepth comparison of 11 medical affairs teamsanswering important questions like:


What do physicians need?


How, and how often are they using your medical affairs team?

What services do they consider most important?

How often should you contact them? What channels are best?


Does your medical affairs team deliver?


How memorable are your team's interactions with doctors?

How do doctors rank your team for performance and satisfaction in 12 key areas?

How does your team compare to the competitionin each area, and overall?


What needs improvement?


Are you delivering the services that are most important to doctors?

Where do you need to improve?

How can your team enhance its services?


Based on Interviews with Practicing Doctors


We surveyed 150 medical oncologists from the EU5 France, Italy, Germany, Spain, UKchosen from the largest community of validated physicians in the world


All respondents:


Have been practicing for between 3 and 35 years

See at least 5 patients with NSCLC ina typical month

Devote at least 50% of their time to direct patient care

Have interacted with at least one listed product's medical affairs team in the past 6 months.


We conducted the survey between February 612, 2018.


Money Back Guarantee!


At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.


About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.


FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering uptotheminute pharma news, insight, analysis and expert views of importance to your company's success.


FirstWord Reports deliver timely, needtoknow intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.


Learn more at www.firstwordgroup.com.

Original Article: Medical Affairs Reputations: NonSmall Cell Lung Carcinoma EU5 2018 [Report Updated: 01022018] Prices from USD $6365

NEXT ARTICLE

More From BioPortfolio on "Medical Affairs Reputations: NonSmall Cell Lung Carcinoma EU5 2018 [Report Updated: 01022018] Prices from USD $6365"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...